improved survival, toxicity & qol with pembrolizumab in head and neck cancer
Published 6 years ago • 172 plays • Length 3:08Download video MP4
Download video MP3
Similar videos
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
0:39
predicting responses to immunotherapy in head and neck cancer
-
1:09
the future role of immunotherapy in head and neck cancers
-
4:29
the role of quality of life in the management of head and neck cancer
-
3:17
the development of immunotherapies in the treatment of relapsed metastatic head and neck cancer
-
2:12
unanswered questions in head and neck cancer
-
1:36
improving survival rates of head and neck cancers
-
2:38
enhanced pembrolizumab efficacy with ephb4-albumin in hpv-negative head and neck cancer | oncotarget
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
1:59
potential of immunotherapy in head and neck cancer
-
2:53
keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc
-
2:14
innovative approaches to the treatment of head and neck cancer
-
1:52
esmo 2022 highlights in head and neck cancer
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
1:27
where to go next with pembrolizumab and other anti-pd-1 therapies in head and neck cancer
-
1:56
eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
3:35
is there a use for anti-pdl-1 antibodies in recurrent head and neck cancer?
-
1:58
dr. vokes on nivolumab, pembrolizumab approvals in head and neck cancer